Frontiers Case report: Short-term eculizumab use in atypical HUS

PDF) First Report on Successful Conversion of Long-Term Treatment of Recurrent Atypical Hemolytic Uremic Syndrome With Eculizumab to Ravulizumab in a Renal Transplant Patient

PDF) Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses

Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study - ScienceDirect

atypical hemolytic uremic syndrome - List of Frontiers' open access articles

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

Frontiers Atypical hemolytic uremic syndrome triggered by mRNA vaccination against SARS-CoV-2: Case report

PDF] Atypical hemolytic uremic syndrome: a syndrome in need of clarity

COVID-19 Triggers Relapse in Woman With aHUS: Case Study

PDF) Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses